4/14
08:30 am
rnxt
Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting
Low
Report
Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting
4/9
08:15 am
rnxt
RenovoRx (RNXT) had its price target raised by Ascendiant Capital Markets from $13.00 to $13.50. They now have a "buy" rating on the stock.
Medium
Report
RenovoRx (RNXT) had its price target raised by Ascendiant Capital Markets from $13.00 to $13.50. They now have a "buy" rating on the stock.
4/8
12:48 pm
rnxt
RenovoRx (RNXT) had its "buy" rating reaffirmed by HC Wainwright. They now have a $3.00 price target on the stock.
Low
Report
RenovoRx (RNXT) had its "buy" rating reaffirmed by HC Wainwright. They now have a $3.00 price target on the stock.
4/8
08:30 am
rnxt
RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum
Medium
Report
RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum
4/4
01:04 am
rnxt
Medium
Report
4/1
03:20 pm
rnxt
RenovoRx Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026 [Yahoo! Finance]
Low
Report
RenovoRx Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026 [Yahoo! Finance]
4/1
02:20 pm
rnxt
RenovoRx Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
Low
Report
RenovoRx Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
3/30
11:11 pm
rnxt
RenovoRx Inc (RNXT) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... [Yahoo! Finance]
Medium
Report
RenovoRx Inc (RNXT) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... [Yahoo! Finance]
3/30
04:05 pm
rnxt
RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update
Medium
Report
RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update
3/26
09:23 am
rnxt
RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment [Yahoo! Finance]
Low
Report
RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment [Yahoo! Finance]
3/26
08:30 am
rnxt
RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment
Medium
Report
RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment
3/23
09:14 am
rnxt
RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement [Yahoo! Finance]
Medium
Report
RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement [Yahoo! Finance]
3/23
08:30 am
rnxt
RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement
Medium
Report
RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement
3/20
09:03 am
rnxt
RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET [Yahoo! Finance]
Low
Report
RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET [Yahoo! Finance]
3/18
09:18 am
rnxt
RenovoRx Announces $10 Million at Market Private Placement [Yahoo! Finance]
Neutral
Report
RenovoRx Announces $10 Million at Market Private Placement [Yahoo! Finance]
3/18
09:12 am
rnxt
RenovoRx announces $10 million private placement [Seeking Alpha]
Low
Report
RenovoRx announces $10 million private placement [Seeking Alpha]
3/18
08:35 am
rnxt
RenovoRx Announces $10 Million at Market Private Placement
Medium
Report
RenovoRx Announces $10 Million at Market Private Placement
3/15
01:05 am
rnxt
High
Report
3/7
02:59 am
rnxt
Low
Report
2/28
09:08 am
rnxt
RenovoRx advances RenovoCath adoption at U.S. cancer centers [Yahoo! Finance]
Low
Report
RenovoRx advances RenovoCath adoption at U.S. cancer centers [Yahoo! Finance]
2/27
08:50 am
rnxt
RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum [Yahoo! Finance]
Medium
Report
RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum [Yahoo! Finance]
2/27
08:30 am
rnxt
RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum
Medium
Report
RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum
2/26
08:54 am
rnxt
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting [Yahoo! Finance]
Medium
Report
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting [Yahoo! Finance]
2/26
08:30 am
rnxt
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting
Medium
Report
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting
2/17
08:03 am
rnxt
RenovoRx (NASDAQ:RNXT) had its price target raised by analysts at Ascendiant Capital Markets from $12.50 to $13.00. They now have a "buy" rating on the stock.
Low
Report
RenovoRx (NASDAQ:RNXT) had its price target raised by analysts at Ascendiant Capital Markets from $12.50 to $13.00. They now have a "buy" rating on the stock.